{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:02:54Z","timestamp":1770620574257,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiology Case Reports"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.radcr.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T19:45:06Z","timestamp":1583437506000},"page":"534-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Fibromyalgia associated with repeated gadolinium contrast-enhanced MRI examinations"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-5961","authenticated-orcid":false,"given":"Silvia Maria","family":"Lattanzio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Imbesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radcr.2020.02.002_bib0001","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1007\/s00234-004-1331-y","article-title":"Perfusion MRI in CNS disease: current concepts","volume":"46","author":"Essig","year":"2004","journal-title":"Neuroradiology"},{"key":"10.1016\/j.radcr.2020.02.002_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","article-title":"25 years of contrast-enhanced MRI: developments, current challenges and future perspectives","volume":"33","author":"Lohrke","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.radcr.2020.02.002_bib0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.berh.2012.07.008","article-title":"Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure","volume":"26","author":"Bernstein","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0004","series-title":"FDA requests boxed warning for contrast agents used to improve MRI images [press release]","year":"2007"},{"key":"10.1016\/j.radcr.2020.02.002_bib0005","series-title":"FDA Briefing Document: Gadolinium retention after gadolinium based contrast magnetic resonance imaging in patients with normal renal function","year":"2017"},{"key":"10.1016\/j.radcr.2020.02.002_bib0006","series-title":"Drug safety communication. FDA evaluating the risk of brain deposits with repeated use of Gadolinium-based contrast agents for magnetic resonance imaging (MRI)","year":"2015"},{"key":"10.1016\/j.radcr.2020.02.002_bib0007","year":"2017"},{"key":"10.1016\/j.radcr.2020.02.002_bib0008","series-title":"FDA drug safety communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings","year":"2018"},{"key":"10.1016\/j.radcr.2020.02.002_bib0009","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.rli.0000112789.57341.01","article-title":"Comparison of Gd-DTPA-BMA (Omniscan) versus Gd-HPDO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy","volume":"39","author":"Gibby","year":"2004","journal-title":"Invest Radiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/01.rli.0000186569.32408.95","article-title":"Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HPDO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled mass spectroscopy","volume":"41","author":"White","year":"2006","journal-title":"Invest Radiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0011","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","article-title":"Macrocyclic and other non\u2013group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: Preliminary results from 9 patients with normal renal function","volume":"51","author":"Murata","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0012","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast enhanced MR imaging","volume":"275","author":"McDonald","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.radcr.2020.02.002_bib0013","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1039\/b905145g","article-title":"Incorporation of excess gadolinium into human bone from medical contrast agents","volume":"1","author":"Darrah","year":"2009","journal-title":"Metallomics"},{"key":"10.1016\/j.radcr.2020.02.002_bib0014","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00234-019-02172-6","article-title":"Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear\/macrocyclic agents","volume":"61","author":"Kiviniemi","year":"2019","journal-title":"Neuroradiology"},{"key":"10.1016\/j.radcr.2020.02.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171704","article-title":"The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review","volume":"12","author":"Olchowy","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radcr.2020.02.002_bib0016","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1148\/radiol.2018171105","article-title":"Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: A observational cohort study","volume":"288","author":"Nehra","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.radcr.2020.02.002_bib0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00062-018-0678-0","article-title":"A review of the current evidence on gadolinium deposition in the brain","volume":"28","author":"Pullicino","year":"2018","journal-title":"Clin Neuroradiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3174\/ajnr.A4378","article-title":"Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration","volume":"36","author":"Adin","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/RLI.0000000000000266","article-title":"High levels of gadolinium deposition in the skin of a patient with normal renal function","volume":"51","author":"Roberts","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/RLI.0000000000000318","article-title":"Presumed gadolinium toxicity in subjects with normal renal function. A report of 4 cases","volume":"51","author":"Semelka","year":"2016","journal-title":"Invest Radiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0021","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.mri.2016.07.016","article-title":"Gadolinium deposition disease: inital description of a disease that has been around for a while: A family of disorders","volume":"34","author":"Semelka","year":"2016","journal-title":"Magn Res Imaging"},{"key":"10.1016\/j.radcr.2020.02.002_bib0022","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.mri.2016.05.005","article-title":"Self-reported gadolinium toxicity: a survey of patients with chronic symptoms","volume":"34","author":"Burke","year":"2016","journal-title":"Magn Res Imaging"},{"key":"10.1016\/j.radcr.2020.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.mri.2016.08.016","article-title":"Gadolinium toxicity: iron and ferroportin as central targets","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.radcr.2020.02.002_bib0024","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.radcr.2020.02.002_bib0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3899\/jrheum.100594","article-title":"Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia","volume":"38","author":"Wolfe","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0026","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.radcr.2020.02.002_bib0027","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AJP.0000000000000354","article-title":"Fibromyalgia and chronic pain syndromes. A white paper detailing current challenges in the field","volume":"32","author":"Arnold","year":"2016","journal-title":"Clin J Pain."},{"key":"10.1016\/j.radcr.2020.02.002_bib0028","first-page":"15","article-title":"Symptoms and signs in fibromyalgia syndrome","volume":"60","author":"Cassisi","year":"2008","journal-title":"Reumatismo"},{"key":"10.1016\/j.radcr.2020.02.002_bib0029","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.0000000000003735","article-title":"Distribution map of gadolinium deposition within the cerebellum following GBCA administration","volume":"88","author":"Roberts","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.radcr.2020.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.mri.2016.09.003","article-title":"Gadolinium deposition: is it chelated of dissociated gadolinium? how can we tell?","volume":"34","author":"Tweedle","year":"2016","journal-title":"Magn Res Imaging"},{"key":"10.1016\/j.radcr.2020.02.002_bib0031","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/cr00081a003","article-title":"Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design","volume":"87","author":"Lauffer","year":"1987","journal-title":"Chem Rev"},{"key":"10.1016\/j.radcr.2020.02.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2019.109240","article-title":"The gadolinium hypothesis for fibromyalgia and unexplained widespread chronic pain","volume":"129","author":"Lattanzio","year":"2019","journal-title":"Med Hyp"},{"key":"10.1016\/j.radcr.2020.02.002_bib0033","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1085\/jgp.95.4.679","article-title":"Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit","volume":"95","author":"Lansman","year":"1990","journal-title":"J Gen Physiol."},{"key":"10.1016\/j.radcr.2020.02.002_bib0034","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1113\/jphysiol.1993.sp019835","article-title":"Block of current through T-type calcium channels by trivalent metal cations and nickel in neural rat and human cells","volume":"469","author":"Mlinar","year":"1993","journal-title":"J Physiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0035","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/0306-4522(82)90019-7","article-title":"The gadolinium ion: a potent blocker of calcium channels and catecholamine release from cultured chromaffin cells","volume":"7","author":"Bourne","year":"1982","journal-title":"Neuroscience"},{"key":"10.1016\/j.radcr.2020.02.002_bib0036","doi-asserted-by":"crossref","first-page":"C515","DOI":"10.1152\/ajpcell.1990.259.3.C515","article-title":"Gadolinium blocks low-threshold and high-threshold calcium currents in pituitary-cells","volume":"259","author":"Biagi","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0037","series-title":"Biochmistry of the Lanthanides","author":"Evans","year":"1990"},{"key":"10.1016\/j.radcr.2020.02.002_bib0038","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/oxfordjournals.jbchem.a134655","article-title":"Characterization of Gd3+ and Tb3+ binding sites on Ca2+, Mg2+ -adenosine triphosphatase of sarcoplasmic reticulum","volume":"95","author":"Itoh","year":"1984","journal-title":"J Biochem (Tokyo)"},{"key":"10.1016\/j.radcr.2020.02.002_bib0039","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/PL00005002","article-title":"Lanthanides inhibit human noradrenaline, 5-hydroxytryptamine and dopamine transporters","volume":"355","author":"Bryan-Lluka","year":"1997","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"10.1016\/j.radcr.2020.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jmri.21966","article-title":"Primer on gadolinium chemistry","volume":"30","author":"Sherry","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radcr.2020.02.002_bib0041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0009-2797(03)00072-3","article-title":"La3+, Gd3+ and Yb3+ induced changes in mitochondrial structure, membrane permeability, cytochrome c release and intracellular ROS level","volume":"146","author":"Liu","year":"2003","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.radcr.2020.02.002_bib0042","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.neuro.2010.04.003","article-title":"Impaired mitochondrial function and oxidative stress in rat cortical neurons: Implications for gadolinium-induced neurotoxicity","volume":"31","author":"Feng","year":"2010","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.radcr.2020.02.002_bib0043","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.chemosphere.2013.11.031","article-title":"Mitochondrial dysfunction induced by different concentrations of gadolinium ion","volume":"100","author":"Zhao","year":"2014","journal-title":"Chemosphere"},{"key":"10.1016\/j.radcr.2020.02.002_bib0044","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/RLI.0000000000000567","article-title":"Gadolinium-based MRI contrast agents induce mitochondrial toxicity and cell death in human neurons, and toxicity increases with reduced kinetic stability of the agent","volume":"54","author":"Bower","year":"2019","journal-title":"Invest Radiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.envres.2017.12.004","article-title":"Delayed-type hypersensitivity to metals in connective tissue diseases and fibromyalgia","volume":"161","author":"Bj\u00f8rklund","year":"2018","journal-title":"Environ Res"},{"key":"10.1016\/j.radcr.2020.02.002_bib0046","first-page":"559","article-title":"Metal-induced inflammation triggers fibromyalgia in metal-allergic patients","volume":"34","author":"Stejskal","year":"2013","journal-title":"Neuroendocrinol Lett."},{"key":"10.1016\/j.radcr.2020.02.002_bib0047","first-page":"753","article-title":"Metals as a common trigger of inflammation resulting in non-specific symptoms: Diagnosis and treatment","volume":"16","author":"Stejskal","year":"2014","journal-title":"IMAJ"},{"key":"10.1016\/j.radcr.2020.02.002_bib0048","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MNH.0000000000000475","article-title":"Gadolinium-based contrast agents: why nephrologists need to be concerned","volume":"28","author":"Leyba","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.radcr.2020.02.002_bib0049","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1067\/j.cpradiol.2018.02.003","article-title":"The impact of gadolinium deposition on radiology practice: An international survey of radiologists","volume":"48","author":"Fitzgerald","year":"2019","journal-title":"Curr Probl Diagn Radiol"},{"key":"10.1016\/j.radcr.2020.02.002_bib0050","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1038\/s41598-018-22511-6","article-title":"Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents","volume":"8","author":"Rees","year":"2018","journal-title":"Sci Rep"}],"container-title":["Radiology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043320300431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1930043320300431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:49:32Z","timestamp":1761824972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1930043320300431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1930043320300431"],"URL":"https:\/\/doi.org\/10.1016\/j.radcr.2020.02.002","relation":{},"ISSN":["1930-0433"],"issn-type":[{"value":"1930-0433","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibromyalgia associated with repeated gadolinium contrast-enhanced MRI examinations","name":"articletitle","label":"Article Title"},{"value":"Radiology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radcr.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.","name":"copyright","label":"Copyright"}]}}